대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Two Weeks VS Four Weeks Use of Atorvastatin to Reduce Hyperlipidemia in Children with Refractory Nephrotic Syndrome: Which One is Better?
저자	Astrid Kristina Kardani
출판정보	2024; 2024(1):
키워드
초록	Objectives: Persistent hyperlipidemia in children with refractory nephrotic syndrome (NS) is a risk factor for endothelial dysfunction, cardiovascular disease and aggravating glomerulosclerosis. There is no official consensus regarding the management of hyperlipidemia in NS. Statin which is often used to reduce cholesterol levels has a dualism effect, in long-term use, it could cause an increase in HMG-CoAR. This research analyze the effects of atorvastatin administration in different durations on HMG-CoAR and LDL cholesterol levels in refractory NS children. Methods: This is an experimental, randomized, double-blind clinical trial in refractory NS children aged 6-18 years with LDL cholesterol ≥130mg/dL in Dr. Soetomo Academic General Hospital, Indonesia. The patient will be randomized to atorvastatin and placebo group in 5 mg dose for ages 6-10 years and 10 mg dose for ≥10 years with two different durations of administration, 2 weeks and 4 weeks administration. Enzyme-linked Immunosorbent Assay (ELISA) was used to measure HMG-CoAR, while LDL was measured by enzymatic end-point method. Data were analyzed using the Mann-Whitney test and independent T-test. Results: Forty children with NS and hyperlipidemia were included in the study, 25 (63%) had steroid-resistant NS, 9 (22%) had frequently relapsing NS and 6 (15%) had steroid-dependent NS. The levels of HMG-CoAR increased significantly in the atorvastatin group after 4 weeks of treatment (P<0,05) whilst the LDL cholesterol levels decreased significantly (p<0,05) in the atorvastatin group after 2 weeks of treatment and showed no decrease in the 4 weeks group. Conclusions: Giving atorvastatin in refractory SN children with hyperlipidemia decreases LDL cholesterol levels after 2 weeks of treatment nonetheless increases levels of HMG-CoAR after 4 weeks of treatment. Evaluation and adjustment of doses every 2 weeks is needed.
원문(PDF)	PDF 원문보기

목록

위로가기